Role of endothelin in noradrenaline-induced hypertension in rats

Journal of Hypertension

Volumn 23, Issue 5, 2005, Pages 987-993

  Boesen, Erika I ^a   Anderson, Warwick P ^a   Kett, Michelle M ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Endothelin; Experimental; Hypertension; Noradrenaline; Rats

Indexed keywords

ENDOTHELIN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR; NORADRENALIN; TAK 044;

ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; TELEMETRY;

EID: 18344365191     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000166839.63312.29     Document Type: Article

References (37)

1. Kohno M, Murakawa K, Yokokawa K, Yasunari K, Horio T, Kurihara N, et al. Production of endothelin by cultured porcine endothelial cells: modulation by adrenaline. J Hypertens Suppl 1989; 7:S130-S131.
2. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415.
3. Kaddoura S, Firth JD, Boheler KR, Sugden PH, Poole-Wilson PA. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist. Circulation 1996; 93:2068-2079.
4. Dao HH, Martens FM, Lariviere R, Yamaguchi N, Cernacek P, de Champlain J, et al. Transient involvement of endothelin in hypertrophic remodeling of small arteries. J Hypertens 2001; 19:1801-1812.
5. Dao HH, Lemay J, de Champlain J, deBlois D, Moreau P. Norepinephrine-induced aortic hyperplasia and extracellular matrix deposition are endothelin-dependent. J Hypertens 2001; 19:1965-1973.
6. Fujita K, Matsumura Y, Kita S, Miyazaki Y, Hisaki K, Takaoka M, et al. Role of endothelin-1 and the ETA receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension. Br J Pharmacol 1995; 114:925-930.
7. Barton M, d'Uscio LV, Shaw S, Meyer P, Moreau P, Luscher TF. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998; 31:499-504.
8. Ballew JR, Fink GD. Role of ET(A) receptors in experimental ANG II-induced hypertension in rats. Am J Physiol 2001; 2B1:R150-R154.
9. Fitzgerald SM, Stevenson KM, Evans RG, Anderson WP. Systemic hemodynamic responses to chronic angiotensin II infusion into the renal artery of dogs. Am J Physiol 1997; 273:R1980-R1989.
10. Ortiz MC, Sanabria E, Manriquez MC, Romero JC, Juncos LA. Role of endothelin and isoprostanes in slow pressor responses to angiotensin II. Hypertension 2001; 37:505-510.
11. Gratton JP, Cournoyer G, Loffler BM, Sirois P, D'Orleans-Juste P. ET(B) receptor and nitric oxide synthase blockade induce BQ-123-sensitive pressor effects in the rabbit. Hypertension 1997; 30:1204-1209.
12. Pollock DM, Opgenorth TJ. Evidence for endothelin-induced renal vasoconstriction independent of ETA receptor activation. Am J Physiol 1993; 264:R222-R226.
13. Gellai M, Fletcher T, Pullen M, Nambi P. Evidence for the existence of endothelin-B receptor subtypes and their physiological roles in the rat. Am J Physiol 1996; 271:R254-R261.
14. Dobrowolski L, Endlich K, Sadowski J, Steinhausen M. Cardiovascular and renal effects of endothelin receptor blockade with PD 145065 and interaction with urodilatin. Acta Physiol Scand 1997; 159:7-13.
15. Ekelund U, Adner M, Edvinsson L, Mellander S. Effects of selective ETB-receptor stimulation on arterial, venous and capillary functions in cat skeletal muscle. Br J Pharmacol 1994; 112:887-894.
16. Henrion D, Laher I. Potentiation of norepinephrine-induced contractions by endothelin-1 in the rabbit aorta. Hypertension 1993; 22:78-83.
17. Zerrouk A, Champeroux P, Safar M, Brisac AM. Role of endothelium in the endothelin-1-mediated potentiation of the norepinephrine response in the aorta of hypertensive rats. J Hypertens 1997; 15:1101-1111.
18. Schilling L, Feger GI, Ehrenreich H, Wahl M. Endothelin-1-induced contraction and relaxation of isolated rat basilar artery: effect of the endothelium. J Cardiovasc Pharmacol 1995; 26(suppl 3):197-199.
19. Abassi ZA, Ellahham S, Winaver J, Hoffman A. The intrarenal endothelin system and hypertension. News Physiol Sci 2001; 16:152-156.
20. Vassileva I, Mountain C, Pollock DM. Functional role of ETB receptors in the renal medulla. Hypertension 2003; 41:1359-1363.
21. Hall JE, Mizelle HL, Woods LL, Montani JP. Pressure natriuresis and control of arterial pressure during chronic norepinephrine infusion. J Hypertens 1988; 6:723-731.
22. King BD, Sack D, Kichuk MR, Hintze TH. Absence of hypertension despite chronic marked elevations in plasma norepinephrine in conscious dogs. Hypertension 1987; 9:582-590.
23. Ames RP, Borkowski AJ, Sicinski AM, Laragh JH. Prolonged infusions of angiotensin II and norepinephrine and blood pressure, electrolyte balance, and aldosterone and cortisol secretion in normal man and in cirrhosis with ascites. J Clin Invest 1965; 44:1171-1186.
24. Katholi RE, Carey RM, Ayers CR, Vaughan ED Jr, Yancey MR, Morton CL. Production of sustained hypertension by chronic intrarenal norepinephrine infusion in conscious dogs. Circ Res 1977; 40:1118-1126.
25. Wang J, Ochoa M, Patel MB, Zucker IH, Loud AV, Zeballos GA, et al. Carotid baroreceptor function in dogs with chronic norepinephrine infusion. Hypertension 1991; 17:745-754.
26. Kleinjans JCS, Smits JFM, Kasbergen CM, Struyker Boudier HAJ. Body fluid and salt homeostasis during hypertension caused by chronic intrarenal norepinephrine infusion in conscious rats. J Hypertens 1983; 1:207-209.
27. Kleinjans JC, Smits JF, van Essen H, Kasbergen CM, Struyker Boudier HA. Hemodynamic characterization of hypertension induced by chronic intrarenal or intravenous infusion of norepinephrine in conscious rats. Hypertension 1984; 6:689-699.
28. Zhao M, Hagler HK, Muntz KH. Regulation of alpha 1-, beta 1-, and beta 2-adrenergic receptors in rat heart by norepinephrine. Am J Physiol 1996; 271:H1762-H1768.
29. Yasujima M, Abe K, Tanno M, Kanazawa M, Yoshida K, Sato M, et al. Depressor mechanism of enalapril in rats made hypertensive by norepinephrine or vasopressin. Nephron 1990; 55(suppl 1):81-84.
30. Reinhart GA, Lohmeier TE, Hord CE Jr. Hypertension induced by chronic renal adrenergic stimulation is angiotensin dependent. Hypertension 1995; 25:940-949.
31. Johnson MD, Grignolo A, Kuhn CM, Schanberg SM. Hypertension and cardiovascular hypertrophy during chronic catecholamine infusion in rats. Life Sci 1983; 33:169-180.
32. Kleinjans J, Kasbergen C, Vervoort-Peters L, Smits J, Struyker Boudier HA. Chronic intravenous infusion of noradrenaline produces labile hypertension in conscious rats. Life Sci 1981; 29:509-514.
33. Kleinjans JC, Smits JF, Kasbergen CM, Vervoort-Peters HT, Struyker Boudier HA. Blood pressure response to chronic low-dose intrarenal noradrenaline infusion in conscious rats. Clin Sci 1983; 65:111-116.
34. Griffin KA, Abu-Amarah I, Picken M, Bidani AK. Renoprotection by ACE inhibition or aldosterone blockade is 4lood 4ressure-dependent. Hypertension 2003; 41:201-206.
35. Kurtz TW. False claims of blood pressure-independent protection by blockade of the renin angiotensin aldosterone system? Hypertension 2003; 41:193-196.
36. Cowley AW Jr, Szczepanska-Sadowska E, Stepniakowski K, Mattson D. Chronic intravenous administration of V1 arginine vasopressin agonist results in sustained hypertension. Am J Physiol 1994; 267:H751-H756.
37. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003; 41:625-633.